Founder & Chairman

Thomas has 25 years of experience in building businesses, incubating technologies and creating completely new categories and markets in the fields of Consumer Health, Biotech and AgTech.

Chief Scientific Officer

Rachael has 20 years’ experience working for global wound management companies in the research and development of medical devices. A biomedical scientist with a PhD and patents relating to biomarkers of infection in chronic wounds. Rachael has led technical and project teams in the design, manufacture and launch of new products.

Chairman

Thomas has 25 years of experience in building businesses, incubating technologies and creating completely new categories and markets in the fields of Consumer Health, Biotech and AgTech.

Executive Director

Bill has over 30 years experience in senior leadership positions with medical device companies such as Smith and Nephew, J&J, Systagenix and Acelity being responsible for new product development, regulatory affairs and quality assurance.

Clinical Advisor

A world-leading key opinion leader in wound care and Visiting Professor at Birmingham City University UK. Formerly serving as the National Clinical and Education Director at the Royal College of Podiatry .

Paul has a Fellowship from the Royal College of Physicians and Surgeons and The Royal College of Podiatry.

Over 50 peer reviewed publications, and Editor of the Diabetic Foot Journal.

International global podium presence and contributor on global advisory boards. 

Contributing author on the World Union Wound Healing Societies Consensus Document, 2019: Wound Exudate; effective assessment and management.

Non-Executive Director

Carin has over 30 years of experience as a banker and builder of businesses in nutraceuticals, medical devices and animal health, focusing on solutions to significant problems. She is an investor, experienced board member and Chairs the board of a large international aid organisation.

Financial Director

Chris is registered with ICAEW and ACCA as both a Chartered and Certified accountant.

Having previously held senior financial positions within international businesses, advised owner-managed, entrepreneurial clients whilst at PwC and other advisory firms, Chris currently manages his own portfolio of business interests.

Scientific Advisor

A biochemist who graduated from the Queen’s University of Belfast in Northern Ireland with BSc(Hons) and PhD, before going to Stony Brook University New York to undertake research to understanding the role of proteases and growth factors in wound repair.

In 1994 Breda joined Johnson & Johnson (J&J) and continued to work in chronic wound repair, most notably providing key supporting scientific data for PROMOGRAN™, PROMOGRAN PRISMA™, for which she was awarded the Johnson Medal, the highest scientific award recognized within J&J.

Breda has worked in the industry for over 30 years continuing to advance clinical and scientific knowledge in the field of wound care. The J&J wound care business was divested, became Systagenix, and was later acquired by Acelity L.P. Inc. in 2013. During her career, Breda was responsible for initiating, leading & supporting clinical and scientific programs within Research & Development, and for providing scientific & technical expertise to the organization. 

This has led to over 30 patents, and over a 100 scientific publications and posters.

Today she is an independent consultant, providing scientific and clinical expertise as well as education globally on the science of wound healing.

Non-Executive Director

Damian Marron is an experienced Board Chair and Non-Executive Director, corporate advisor and former serial CEO with a successful track record of value creation through public and venture capital financing, portfolio planning, M&A, licensing agreements and R&D collaborations, both as an executive and in advisory roles.

Damian is currently Non-Executive Chair of the Board at Circio ASA,  Imophoron Ltd and Indegra Tx Ltd and Non-Executive Director at Cantargia AB and Resolys Bio Inc.

He is also Head of Biopharma with Treehill Partners, a global pure-play healthcare advisory firm and is a Biotech Advisor to Mendel Partners.

Damian has formerly been Chair of the Board of Directors of PepGen Ltd and CytoSeek Ltd and the CEO at Agalimmune Ltd, TxCell SA, Cytheris SA, and Trophos SA. He is a pharmacologist and cell biologist by training and spent ten years in big pharma R&D.

Clinical Advisor

Keith has had a longstanding interest in wound healing and is a world leading KOL.  He was appointed as the first Director of the Wound Healing Research Unit in 1991.  From 2011 – 2013 he was Director of TIME Institute (Translation, Innovation, Methodology and Engagement) and Head of Wound Healing Research Unit, School of Medicine, Cardiff University and Clinical Lead for Wound Healing in the Cardiff & Vale NHS Trust.  In 2013 he was appointed as Dean of Clinical Innovation at Cardiff University and in 2014 was appointed as Medical Director of the Welsh Wound Innovation Centre (WWIC).